Stocks · News reference
Ginkgo Bioworks announced its third-quarter 2026 financial results, highlighting the first sale of its autonomous lab platform and reaffirmed cash-burn guidance.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Dr. Catherine Cifuentes-Rojas, Director and Lead for Genetic Medicines and Biologics at Ginkgo Bioworks, has published a data-driven checklist designed to assist R&D teams in evaluating early-stage biotherapeutic programs.
Dr. Catherine Cifuentes-Rojas, Director and Lead for Genetic Medicines and Biologics at Ginkgo Bioworks, has formalized a personal commitment to monthly reverse mentorship sessions with junior staff.
Ginkgo Bioworks has announced it will host a presentation and Q&A session to discuss its third-quarter 2026 business performance on November 5, 2026.
Cathie Wood's Ark Invest has been buying Archer Aviation stock during its 62% decline, but the article examines Ark's track record of buying beaten-down stocks. Ark Innovation ETF has underperformed the S&P 500 by 110% over five years, with notable losses in past holdings like Teladoc (down 95%), Zoom (down 65%), and Ginkgo Bioworks (down 98%). The article cautions that investors should evaluate Archer based on its own business fundamentals and catalysts rather than Ark's historical performance.
TD Cowen analyst Brendan Smith maintains Ginkgo Bioworks Holdings (NYSE:DNA) with a Hold and raises the price target from $9 to $11.
Glaukos reports positive Phase 4 results for its iDose TR therapy, demonstrating superior efficacy over standalone cataract surgery.